SomaLogic significantly expands key strategic collaboration with Novartis

Wednesday, October 23, 2019

Ten-year agreement with Novartis demonstrates broad and deep commitment to accelerating disease and therapeutic-specific insights based on proprietary proteomic technology

Boulder, Colo., USA — SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts. The agreement includes plans to analyze at least 250,000 clinical samples from across the Novartis drug development portfolio.

“Our ongoing collaboration with our Novartis colleagues, which began in 2011 and was extended in 2014, has been instrumental in both developing and validating the value of our SomaScan Platform,” said Roy Smythe, M.D., CEO of SomaLogic. “Today, our technology is being used to inform research efforts around the world, promote individual health and wellness, and augment clinical decision-making.”

Under this new agreement, Novartis will expand its access to the SomaScan® Platform, which currently measures approximately 5000 human proteins in a small amount of biological sample. The SomaScan Platform enables Novartis to discover new insights into the biology of disease and the variability of drug response, develop new biomarkers that better target high-responder populations, and then apply these insights to the design of their clinical trials and commercial programs. In turn, this collaboration will assist SomaLogic to grow its clinical proteomics database and expand its growing pipeline of precision health information products. These products are aimed at helping individuals optimize their health and wellness as well as proactively manage many diseases and conditions.

“By continuing our collaboration with SomaLogic and incorporating proteomics into our development programs, alongside our genomics capabilities and deep analysis of our vast historical data resources, we aim to achieve unprecedented insight into human physiology,” said John Tsai, Head of Global Drug Development and Chief Medical Officer at Novartis. “Deciphering the complex interaction of protein networks in the body could unlock an additional therapeutic approach for treating the unmet needs of patients.”

Specific terms of the agreement, including financials and milestones, were not disclosed.


SomaLogic Contact:
Laura S. Mizoue, Ph.D.
Communications Specialist

About SomaLogic
SomaLogic seeks to deliver meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from the precise, proprietary, and personalized measurement of health-related changes in an individual’s proteins over time. For more information, visit and follow @somalogic on Twitter.

Continue Reading

Securisyn Medical Receives FDA 510(k) Clearance for its SolidAIRity™ III Airway Stabilization System

Monday, October 14, 2019

HIGHLANDS RANCH – October 9, 2019 – Securisyn Medical, LLC, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its SolidAIRity™ III Airway Stabilization System (“SolidAIRity™”) for airway management of patients requiring oral intubation. The company, dedicated to making airway management safer, has pioneered the first, fully integrated airway stabilization system designed and patented to provide unmatched airway stability for ventilated patients.

Denver Business Journal Highlights Colorado’s Life Sciences Ecosystem and Our Leadership In Gene Editing

Monday, September 09, 2019

Gene editing is becoming an increasingly common remedy for a variety of ailments, and Boulder area bioscience companies are leading those advancements. Building on research and technology originating at University of Colorado Boulder, several front range companies are employing CRISPR to create new breakthroughs.  

2019 Rocky Mountain Life Science Investor and Partnering Conference Announces Presenting Companies

Wednesday, July 24, 2019

September conference led by Colorado BioScience Association to provide companies from across the region new opportunities for capital access 
Continue Reading

Pfizer to buy Colorado's Array BioPharma in deal worth $11.4 billion

Monday, June 17, 2019

Pharmaceutical giant Pfizer Inc. is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma Inc., a Colorado drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring.

Pfizer said Monday it will pay $48 per share in cash for Boulder-based Array, whose product portfolio includes a treatment combination used for advanced skin cancer that is being tested in other cancers as well.

Array said last month that its combination of the drugs Braftovi and Mektovi along with another treatment led to a significant improvement in overall survival in late-stage testing for some patients with colorectal cancer.

The company plans to submit results from that study to U.S. regulators for approval later this year.

Array's share price has jumped 41% since late May and more than doubled so far this year. Pfizer's offer of $48 per share represents a premium of 62% to the stock's closing price of $29.59 on Friday.

Shares of Array surged 60% before Monday's opening bell.

New York-based Pfizer, which makes the breast cancer drug Ibrance and the blood thinner Eliquis, said the boards of both companies have approved the deal.

It will finance the deal with debt and cash, and it expects the transaction to add to earnings per share starting in 2022.

Pfizer, the biggest U.S. drugmaker by revenue, has had several drug approvals in the U.S. or elsewhere so far this year. But it also saw a heavily touted pain drug flop in late-stage clinical testing, placing the drug's future in doubt.

Pfizer shares edged down 5 cents to $42.70 in premarket trading.

Continue Reading

National Bioscience Industry Report Shows $2T Economic Impact, Accelerated Venture Capital Investment & Job Growth

Tuesday, June 05, 2018

A study released today at the BIO International Convention shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator. 

Just-Released Economic Data Finds Improving Education in Colorado Would Generate Billions for the Economy

Tuesday, May 15, 2018

Continue Reading

Denver Business Journal Recognizes Colorado BioScience's Remarkable Year!

Thursday, December 14, 2017

The Denver Business Journal wants their readers to know the bioscience industry in our state has enjoyed a record breaking year.  

Four Companies Win Their Share of $150,000 in Healthcare Shark-Tank Event

Thursday, October 26, 2017

During the 2017 Prime Health Challenge, six healthcare technology startups pitched to representatives from 16 host institutions, including Kaiser Permanente, Metro Community Provider Network, AllHealth Network, Centura, UCHealth, and SCL Health. Over 500 audience members watched as each company competed for an opportunity to prove their solutions with Colorado healthcare institutions.

Early this summer, companies from around the country submitted applications to compete in the Prime Health Challenge. Over the past 3-months, experts from across the industry evaluated the proposals through the Prime Health Qualify process and narrowed the list down to six finalists. Thanks to funding from The Colorado Health Foundation, winners were rewarded with a share of the $150,000 prize.

“The Colorado Health Foundation is excited about its continued partnership with Prime Health in order to support the intersection of health care, innovation and low income communities across Colorado” said Ben Bynum, M.D., Portfolio Director of Private Sector Engagement at The Colorado Health Foundation.

Steve Adams, CEO of Prime Health, explained, “The healthcare industry presents unique challenges for entrepreneurs. Collaborating with providers and patients early on is key to success and for the winners of tonight’s Challenge, this experience will provide invaluable knowledge on how to scale innovation in the healthcare industry.”

Nymbl receives their award.

The first place award of $45,000 went to Nymbl Science, who has developed a comprehensive system for measuring, tracking, and improving balance for patients at-risk of falls.

“It was a dream come true for Nymbl to get pilot offers from four of the largest healthcare providers in the state of Colorado, and we are honored to receive the prize money to help make these pilots a reality. We are extremely thankful for the opportunity to pitch and for the sponsors of Prime Health. It was humbling to be on stage with so many other terrific companies, each talented enough to win, and all of which will impact healthcare in significant ways,” said Edward Likovich, Vice President of Operations at Nymbl.

AI Health, which has created a platform to improve communication between hospitals and post-acute care settings, such as, nursing homes, skilled nursing facility, home health, and rehab facilities, won the Safety Net Award. This award of $45,000 was specifically designated for a startup that addressed pain points for underserved populations.

As Dr. Kenneth Bellian, Co-Founder of AI Health, described, "We are very thankful to Prime Health, Colorado Health Foundation and all the participating host institutions for putting together such a wonderful program. We are very excited to have won the Safety Net Award because we know that we can help patients of any background find the best post-acute care facilities based on their specific situation. This results in better outcomes for the patient and lower costs for the payer. This is especially important for patients that are at risk, underfunded, and/or unfunded."

The second place award of $35,000 went to Redox, a Wisconsin-based startup who provides health systems with a platform that acts as a single access point for all cloud-based applications, providing access controls and monitoring while eliminating integrations. Through this, the company hopes to empower innovation and ease the burden of EHR interoperability.

The Third Place of $25,000 went to Listen.MD, an artificial intelligence based scribing application that allows providers to focus on personal interactions with patients.

While only the top four companies won a share of the prize money, all six finalists received bids to pilot their solutions at a host institution. For more information on these companies, and to stay up to date on all the trends in Colorado digital health innovation, visit

Continue Reading

Denver Named a Top 10 City for Digital Health Funding

Thursday, July 06, 2017

Denver made the cut as a top 10 city in the US for digital health funding, with five deals topping $192M total in the first half of 2017. With the mid-year funding now coming in over $6B, 2017 has broken numerous records and we anticipate this to be the biggest year yet as huge deals continue to close.